Evaluation of Experimental Heat Patch

NCT01841788 | Completed DMC

• 1 other identifier: 2012006
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

A disposable, air-activated, adhesive backed heat patch is being developed to provide temporary relief from minor muscular ache and joint pains associated with overexertion strains and sprains as well as minor pain associated with arthritis. The aim of the study is to determine the safety and tolerability of the patch during normal wear conditions.

Conditions

Effects of Heat; Tolerability; Adhesiveness; Dermal Irritation

Outcome Measures

Primary Outcomes (1)

• Irritation Evaluation

  A trained skin grader will apply a predetermined scale to the observed skin reactions in the test areas under light supplied by a 100-watt incandescent blue bulb.

  8 hours

Secondary Outcomes (1)

• Adhesion Evaluation

  8 Hours

Other Outcomes (1)

• Heat Intensity

  8 hours

Study Arms (3)

Thermal Adhesion Patch

EXPERIMENTAL

Group of subjects wearing the experimental patch for 8 hour study duration

Device: Thermal Adhesion Patch

Marketed Thermal Adhesion Patch

ACTIVE COMPARATOR

Group of subjects wearing comparative predicate device for 8 hour study duration.

Device: Marketed Thermal Adhesion Patch

Placebo Patch

PLACEBO COMPARATOR

Group of subjects wearing the placebo patch for 8 hour study duration

Device: Placebo Patch

Interventions

Thermal Adhesion Patch DEVICE

Thermal Adhesion Patch

Marketed Thermal Adhesion Patch DEVICE

Also known as: ThermaCare Heat Wraps

Marketed Thermal Adhesion Patch

Placebo Patch DEVICE

Placebo Patch

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are 18-70 years of age;
• must be in general good health;
• must have absence of any visible disease that might be confused with a skin reaction to the test material;
• Participant's back region must be free of excessive hair, cuts, tattoos, or other aberrations;
• must understand and sign Informed Consent;
• must be considered dependable and able to follow directions;
• must be willing to restrict their activity for the 8 hour patch wear time so that the patches/thermocouples do not come loose;
• must be willing to wear a pouch containing the thermostat and thermocouple wiring for the entire 8 hour period and to return all study supplies to the site at Visit 3. If the items are not returned subject may be invoiced for the value of the unit;
• must be willing not to use any topical products such as lotions, sunscreens, etc. in the test area while participating on the study;
• must agree to use an adequate means of birth control which include: abstinence, partner vasectomy, Intrauterine Device, hormonal implant devices/injections, regular use of birth control pills, birth control patches or condoms with a spermicidal agent;
• Participants are willing to come in with a CLEAN back;
• Participants who are 55 years of age or older, agree to supply a t-shirt to wear at visit two that can be marked on with a marker.

You may not qualify if:

• Participants with known skin sensitivity to adhesion products;
• Participants with any skin abnormality likely to be aggravated by the study material such as dermatological disease or infection, rash, atrophic, fragile, or abnormally dry skin, cuts or abrasions at the treatment site;
• Participants who are pregnant or nursing, oral interview only;
• Participants with diabetes or poor circulation;
• Participants unable to tolerate conditions of protocol;
• Participants viewed by the investigator as not being suitable for the study;
• Participants who have had active skin cancer including basal cell carcinoma, or other cancer within one year;
• Participants who are currently participating in another clinical trial;
• Participants who routinely use anti-inflammatory medications (within 5 days of study start (81mg Aspirin is okay)) or immunosuppressive or antihistamine medications within 3 weeks prior to study start (steroid nose/eye drops are ok);
• Participants who currently use allergy injections;
• Participants with history of severe asthma;
• Participants with active or uncontrolled immunologic disorders i.e. AIDS, HIV positive, systemic lupus erythematosus, rheumatoid arthritis;
• Participants with uncontrolled thyroid disease;
• Participants who have any clinically significant chronic illness which could place the subject at increased risk during participation or result in inappropriate dermal response during the study;
• Participants who have used topical medications at the test sites within the past 14 days;

Sponsors & Collaborators

• Chattem, Inc.: lead

Study Sites (1)

Radiant Research, Inc.

Pinellas Park, Florida, 33781, United States

Location

Study Officials

• Daniel J Hogan, MD

  Radiant Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2013
• First Posted: April 29, 2013
• Study Start: October 1, 2012
• Primary Completion: October 1, 2012
• Study Completion: October 1, 2012
• Last Updated: March 17, 2017

Record last verified: 2013-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)